Learn About Diffuse Midline Glioma H3 K27M-Mutant

View Main Condition: Brain Tumor

What is the definition of Diffuse Midline Glioma H3 K27M-Mutant?
Diffuse intrinsic pontine glioma (DIPG) is a type of aggressive brain tumor that occurs in the pons, part of the brainstem. The pons is important for many bodily functions, including regulating breathing, heart rate, bladder control, balance, and more.  Diffuse intrinsic pontine glioma primarily affects children, with roughly 150-300 new diagnoses per year.
Save information for later
Sign Up
What are the causes of Diffuse Midline Glioma H3 K27M-Mutant?
The cause of diffuse intrinsic pontine glioma is not currently known. Research is being done to identify if certain genetic mutations may be causing DIPG.
What are the symptoms of Diffuse Midline Glioma H3 K27M-Mutant?
Symptoms of diffuse intrinsic pontine glioma often develop quickly. Symptoms may include poor coordination, arm and leg weakness, as well as difficulty controlling eye movements and facial expressions. Some individuals may experience difficulty speaking or eating as well.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Diffuse Midline Glioma H3 K27M-Mutant?
The main treatments for diffuse intrinsic pontine glioma currently include radiation therapy and experimental chemotherapy.  Radiation therapy is generally used for newly diagnosed DIPG. Radiation therapy involves the use of high-energy beams, including X-rays or protons, to destroy tumor cells. Various clinical trials have shown that routine chemotherapy is not effective for treating DIPG. Newer treatments combine chemotherapy with biologic therapy that directly target the tumor.  Because of the tumor's location in the brainstem, it is rarely possible to perform surgery without risk of causing neurological damage.
Who are the top Diffuse Midline Glioma H3 K27M-Mutant Local Doctors?
Elite
Elite
 
 
 
 
Learn about our expert tiers
Learn more
Elite
What is the outlook (prognosis) for Diffuse Midline Glioma H3 K27M-Mutant?
The prognosis for diffuse intrinsic pontine glioma is very poor. Although there is no cure, a small percentage of patients survive.
What are the latest Diffuse Midline Glioma H3 K27M-Mutant Clinical Trials?
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

Summary: This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation. It also tests whether combination of selinexor and standard radiation therapy works to shrink...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor (CAR) T Cells (GD2CART) for Diffuse Intrinsic Pontine Gliomas (DIPG) and Spinal Diffuse Midline Glioma (DMG)

Summary: The primary purpose of this study is to test whether GD2-CAR T cells can be successfully made from immune cells collected from children and young adults with H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) or spinal H3K27M-mutant diffuse midline glioma (DMG). H3K27Mmutant testing will occur as part of standard of care prior to enrollment.

What are the Latest Advances for Diffuse Midline Glioma H3 K27M-Mutant?
Immunotherapy approaches for the treatment of diffuse midline gliomas.
Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma.
Tired of the same old research?
Check Latest Advances
Nimotuzumab as Additional Therapy for GLIOMA in Pediatric and Adolescent: A Systematic Review.
What are some Advocacy Organizations?
keep-punching-brain-cancer

Keep Punching supports patients, healthcare providers, and researchers in their fight to prevent and eradicate brain cancer and minimize treatment-related side effects that may adversely impact function and comfort.